Detalhe da pesquisa
1.
Camrelizumab plus famitinib in previously chemo-immunotherapy treated patients with advanced NSCLC: results from an open-label multicenter phase 2 basket study.
Cancer Immunol Immunother
; 73(7): 124, 2024 May 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-38727837
2.
Special issue "The advance of solid tumor research in China": FGFR4 alterations predict efficacy of immune checkpoint inhibitors in nonsmall cell lung cancer.
Int J Cancer
; 152(1): 79-89, 2023 01 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-36062503
3.
KEYNOTE-033: Randomized phase 3 study of pembrolizumab vs docetaxel in previously treated, PD-L1-positive, advanced NSCLC.
Int J Cancer
; 153(3): 623-634, 2023 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-37141294
4.
On-treatment blood TMB as predictors for camrelizumab plus chemotherapy in advanced lung squamous cell carcinoma: biomarker analysis of a phase III trial.
Mol Cancer
; 21(1): 4, 2022 01 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34980131
5.
ICI plus chemotherapy prolonged survival over ICI alone in patients with previously treated advanced NSCLC.
Cancer Immunol Immunother
; 71(1): 219-228, 2022 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-34097116
6.
Loss of STING expression is prognostic in non-small cell lung cancer.
J Surg Oncol
; 125(6): 1042-1052, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35099823
7.
Exosomes transmit T790M mutation-induced resistance in EGFR-mutant NSCLC by activating PI3K/AKT signalling pathway.
J Cell Mol Med
; 24(2): 1529-1540, 2020 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-31894895
8.
EGFR-targeted therapy alters the tumor microenvironment in EGFR-driven lung tumors: Implications for combination therapies.
Int J Cancer
; 145(5): 1432-1444, 2019 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30784054
9.
EGFR-TKIs plus local therapy demonstrated survival benefit than EGFR-TKIs alone in EGFR-mutant NSCLC patients with oligometastatic or oligoprogressive liver metastases.
Int J Cancer
; 144(10): 2605-2612, 2019 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-30387880
10.
Molecular and clinical analysis of Chinese patients with anaplastic lymphoma kinase (ALK)-rearranged non-small cell lung cancer.
Cancer Sci
; 110(10): 3382-3390, 2019 Oct.
Artigo
em Inglês
| MEDLINE | ID: mdl-31444835
11.
Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Cancer
; 125(7): 1038-1049, 2019 04 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-30548240
12.
Pretreatment neutrophil-to-lymphocyte ratio is associated with outcome of advanced-stage cancer patients treated with immunotherapy: a meta-analysis.
Cancer Immunol Immunother
; 67(5): 713-727, 2018 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-29423649
13.
Frequency of the acquired resistant mutation T790 M in non-small cell lung cancer patients with active exon 19Del and exon 21 L858R: a systematic review and meta-analysis.
BMC Cancer
; 18(1): 148, 2018 02 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29409466
14.
Outcomes of Pemetrexed-based chemotherapies in HER2-mutant lung cancers.
BMC Cancer
; 18(1): 326, 2018 03 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-29587667
15.
Comprehensive evaluation of NT5E/CD73 expression and its prognostic significance in distinct types of cancers.
BMC Cancer
; 18(1): 267, 2018 03 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29514610
16.
Clinical features of Bim deletion polymorphism and its relation with crizotinib primary resistance in Chinese patients with ALK/ROS1 fusion-positive non-small cell lung cancer.
Cancer
; 123(15): 2927-2935, 2017 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-28346673
17.
Uncommon EGFR mutations in a cohort of Chinese NSCLC patients and outcomes of first-line EGFR-TKIs and platinum-based chemotherapy.
Chin J Cancer Res
; 29(6): 543-552, 2017 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-29353977
18.
Epidemiological study of HER-2 mutations among EGFR wild-type lung adenocarcinoma patients in China.
BMC Cancer
; 16(1): 828, 2016 10 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-27793199
19.
Hepatic Metastases is Associated with Poor Efficacy of Erlotinib as 2nd/3rd Line Therapy in Patients with Lung Adenocarcinoma.
Med Sci Monit
; 22: 276-83, 2016 Jan 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-26811313
20.
High Expression of Cathepsin E is Associated with the Severity of Airflow Limitation in Patients with COPD.
COPD
; 13(2): 160-6, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26488201